The University of Southampton
University of Southampton Institutional Repository

Development of a whole cell vaccine for acute myeloid leukaemia

Development of a whole cell vaccine for acute myeloid leukaemia
Development of a whole cell vaccine for acute myeloid leukaemia
We describe the modification of tumour cells to enhance their capacity to act as antigen presenting cells with particular focus on the use of costimulatory molecules to do so. We have been involved in the genetic modification of tumour cells to prepare a whole cell vaccine for nearly a decade and we have a particular interest in acute myeloid leukaemia (AML). AML is an aggressive and difficult to treat disease especially for patients for whom haematopoietic stem cell (HSC) transplant is not an option. AML patients who have a suitable donor and meet HSC transplant fitness requirements, have a 5 year survival of 50%, however for patients with no suitable donor or for which age is a factor, the prognosis is much worse. It is particularly poor prognosis patients, who are not eligible for HSC transplant, who are likely to benefit most from immunotherapy. It would be hoped that immunotherapy would be used to clear residual tumour cells in these patients in the first remission following standard chemotherapy treatments and that this will extend the remission and reduce the risk of a second relapse associated with disease progression and poor mortality rates. In this symposia report we will focus on whole cell vaccines as an immunotherapeutic option with particular reference to their use in the treatment of AML. We will aim to provide a brief overview of the latest data from our group and considerations for the use of this treatment modality in clinical trials for AML
costimulatory molecules, acute myeloid leukaemia, whole cell vaccines, 4-1BB ligand, immunotherapy, tumor immunity
0340-7004
68-75
Cheuk, Adam T.C.
fd9f3583-c275-435d-9878-ebc58eaa1d97
Chan, Lucas
c134b358-dbcb-4f96-95fd-c7c2d43a9ee9
Czepulkowski, Barbara
acbeb262-2c4f-4957-9051-a282104ce8f9
Berger, Stuart A.
a2c10a23-73a1-47bd-bc7a-ff83aca6bf25
Yagita, Hideo
00a66ce4-d0bf-464f-a28c-20dd2fd652ec
Okumura, Ko
3f6ccb82-6b44-4d6e-961a-ecbc5737296e
Farzaneh, Farzin
4d23cf63-efe4-4a52-93cf-504776bffcfb
Mufti, Ghulam J.
940de420-bc41-4006-8517-f2c926ba70aa
Guinn, Barbara-ann
728d28c9-a23d-413a-ba1d-4531005705d7
Cheuk, Adam T.C.
fd9f3583-c275-435d-9878-ebc58eaa1d97
Chan, Lucas
c134b358-dbcb-4f96-95fd-c7c2d43a9ee9
Czepulkowski, Barbara
acbeb262-2c4f-4957-9051-a282104ce8f9
Berger, Stuart A.
a2c10a23-73a1-47bd-bc7a-ff83aca6bf25
Yagita, Hideo
00a66ce4-d0bf-464f-a28c-20dd2fd652ec
Okumura, Ko
3f6ccb82-6b44-4d6e-961a-ecbc5737296e
Farzaneh, Farzin
4d23cf63-efe4-4a52-93cf-504776bffcfb
Mufti, Ghulam J.
940de420-bc41-4006-8517-f2c926ba70aa
Guinn, Barbara-ann
728d28c9-a23d-413a-ba1d-4531005705d7

Cheuk, Adam T.C., Chan, Lucas, Czepulkowski, Barbara, Berger, Stuart A., Yagita, Hideo, Okumura, Ko, Farzaneh, Farzin, Mufti, Ghulam J. and Guinn, Barbara-ann (2006) Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunology Immunotherapy, 55 (1), 68-75. (doi:10.1007/s00262-005-0674-5).

Record type: Article

Abstract

We describe the modification of tumour cells to enhance their capacity to act as antigen presenting cells with particular focus on the use of costimulatory molecules to do so. We have been involved in the genetic modification of tumour cells to prepare a whole cell vaccine for nearly a decade and we have a particular interest in acute myeloid leukaemia (AML). AML is an aggressive and difficult to treat disease especially for patients for whom haematopoietic stem cell (HSC) transplant is not an option. AML patients who have a suitable donor and meet HSC transplant fitness requirements, have a 5 year survival of 50%, however for patients with no suitable donor or for which age is a factor, the prognosis is much worse. It is particularly poor prognosis patients, who are not eligible for HSC transplant, who are likely to benefit most from immunotherapy. It would be hoped that immunotherapy would be used to clear residual tumour cells in these patients in the first remission following standard chemotherapy treatments and that this will extend the remission and reduce the risk of a second relapse associated with disease progression and poor mortality rates. In this symposia report we will focus on whole cell vaccines as an immunotherapeutic option with particular reference to their use in the treatment of AML. We will aim to provide a brief overview of the latest data from our group and considerations for the use of this treatment modality in clinical trials for AML

Full text not available from this repository.

More information

Published date: January 2006
Keywords: costimulatory molecules, acute myeloid leukaemia, whole cell vaccines, 4-1BB ligand, immunotherapy, tumor immunity

Identifiers

Local EPrints ID: 71572
URI: http://eprints.soton.ac.uk/id/eprint/71572
ISSN: 0340-7004
PURE UUID: 8abb614d-b816-4612-aa69-38cb4aa50d4b

Catalogue record

Date deposited: 14 Dec 2009
Last modified: 19 Jul 2019 23:44

Export record

Altmetrics

Contributors

Author: Adam T.C. Cheuk
Author: Lucas Chan
Author: Barbara Czepulkowski
Author: Stuart A. Berger
Author: Hideo Yagita
Author: Ko Okumura
Author: Farzin Farzaneh
Author: Ghulam J. Mufti
Author: Barbara-ann Guinn

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×